Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Dexmedetomidine vs Zolpidem for Primary Insomnia
NCT05615727Phase 3Unknown
- Sponsor
- The University of Hong Kong
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexmedetomidine in Insomnia (3 arms), sponsored by The University of Hong Kong. Primary endpoint: Sleep onset latency at 720 minutes. Status: unknown.
02
Drugs
dexmedetomidine
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT05615727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05615727.